{"id":"gsk4532990","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, GSK4532990 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"GSK4532990 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:01:27.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/ARO-HSD","title":"ARO-HSD","extract":"ARO-HSD, also known as GSK4532990, is a small interfering RNA developed for the treatment of fatty liver disease. Based on the observation that \"loss-of-function HSD17β13 mutations protect against the development of chronic liver disease,\" the therapeutic attempts to induce this loss of function and thus improve liver disease. The therapy is developed by a partnership of GlaxoSmithKline and Arrowhead Pharmaceuticals that might be worth more than $1 billion."},"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05583344","phase":"PHASE2","title":"Phase 2b Study of GSK4532990 in Adults With NASH","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-01-02","conditions":"Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease","enrollment":284},{"nctId":"NCT06613698","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-27","conditions":"Liver Diseases, Alcoholic","enrollment":393},{"nctId":"NCT06104319","phase":"PHASE2","title":"Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-01-22","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK4532990","genericName":"GSK4532990","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK4532990 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}